$3.29
-0.01 (-0.30%)
Open$3.28
Previous Close$3.30
Day High$3.30
Day Low$3.11
52W High$13.93
52W Low$1.90
Volume—
Avg Volume38.2K
Market Cap6.53M
P/E Ratio—
EPS$-1.24
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,010.3% upside
Current
$3.29
$3.29
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.83M | 3.19M | 899.1K |
| Net Income | -3,452,089 | -2,582,824 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -3,650,165 | -2,882,747 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |